All In MedTech

Device Trial Radar · NCT02117349

Topical Raplixa for Surgical Bleeding in Children

A Phase 2, Randomized, Single-Blind, Controlled Trial of Topical Raplixa™ (Fibrin Sealant [Human]) in Intraoperative Surgical Hemostasis in a Pediatric Population

Last checked: Nov 20, 2026Latest source record: Feb 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

55

Actual

Start

Dec 4, 2014

Primary completion

Nov 17, 2017

Study completion Mar 6, 2018

Sponsor

Lead sponsor
MallinckrodtNot on our public-company list
Sponsor type
Industry
First posted
Apr 17, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine if Raplixa plus Gelfoam is better than Gelfoam alone in stopping mild to moderate bleeding in children having surgery.

Conditions

  • Surgical Bleeding

Interventions

  • RaplixaDrug

    Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.

  • GelfoamDevice

    Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.

  • Rescue treatmentDrug

    Thrombin-containing hemostats included in standard care at the site

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Reached Hemostasis at the Target Bleeding Site (TBS) Within 4 MinutesTime frame: within 4 minutes

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Burn Center at Maricopa Medical Center

    Phoenix, Arizona

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.